Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomide Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is indicated for hematologic malignancies and related disorders.

- Multiple myeloma: improves progression‑free survival and overall response when used in approved combination regimens. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts. - Follicular lymphoma (relapsed/refractory): used to achieve disease control in patients who have failed prior therapy.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to easy bruising. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions or itching. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound drop in neutrophils with fever. - Severe thrombocytopenia: risk of serious bleeding. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate baseline health status and monitor patients regularly. - Monitor blood counts: perform complete blood count weekly during the first cycles. - Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use effective contraception: both male and female patients must avoid pregnancy. - Pregnancy: contraindicated or unknown safety; avoid use during pregnancy and lactation. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, DOACs): increased risk of thromboembolic events. - Live vaccines: heightened risk of infection due to immunomodulation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase drug levels. - Immunosuppressants (e.g., cyclosporine, tacrolimus): additive immunosuppression. - Other myelosuppressive agents (e.g., chemotherapy, azacitidine): enhanced bone‑marrow suppression.